---
title: Importance of Meal Fat Content and Gall Bladder Emptying for Postprandial GLP-1 Secretion in Type 2 Diabetes Patients
nct_id: NCT01374594
overall_status: COMPLETED
sponsor: University Hospital, Gentofte, Copenhagen
study_type: OBSERVATIONAL
primary_condition: Diabetes
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01374594.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01374594"
ct_last_update_post_date: 2013-01-23
last_seen_at: "2026-05-12T06:22:09.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Importance of Meal Fat Content and Gall Bladder Emptying for Postprandial GLP-1 Secretion in Type 2 Diabetes Patients

**NCT ID:** [NCT01374594](https://clinicaltrials.gov/study/NCT01374594)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** University Hospital, Gentofte, Copenhagen
- **Conditions:** Diabetes
- **Start Date:** 2011-06
- **Completion Date:** 2012-11
- **CT.gov Last Update:** 2013-01-23

## Brief Summary

PURPOSE

The goal of the present project is to unravel the importance of bile acid-induced GLP-1 secretion (via the G protein-coupled receptor TGR5) in human physiology.

In the present study the investigators examine the GLP-1 secretion in healthy subjects and in Type 2 Diabetes Mellitus (T2DM) patients. The investigators hypothesize that patients with T2DM of relatively long duration will be characterized by reduced gall bladder emptying, and, consequently, reduced intestinal TGR5 activation; resulting in attenuated postprandial GLP-1 responses (primary endpoint).

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria: (Healthy)

* HbA1 \< 6 %
* Normal haemoglobin levels
* Informed content

Inclusion Criteria: (T2DM)

* T2DM \> 5 years
* Normal haemoglobin levels
* Informed content

Exclusion Criteria: (T2DM)

* Treatment with insulin, DPP-IV inhibitor or GLP-1 analogues
* Obesity (BMI \> 30)
* Age \> 70 years
* Gastrointestinal disease
* Nephropathy
* Liver disease
* Medication which cannot be on hold for 12h
* Gastrointestinal surgery

Exclusion Criteria: (Healthy)

* 1st degree relatives with diabetes
* Obesity (BMI \> 30)
* Age \> 70 years
* Gastrointestinal disease
* Nephropathy
* Liver disease
* Medication which cannot be on hold for 12h
* Gastrointestinal surgery
```

## Arms

- **Healthy adults**
- **Type 2 diabetes**

## Primary Outcomes

- **GLP-1 secretion** _(time frame: Postprandial)_

## Locations (1)

- Gentofte University Hospital, Hellerup, Denmark

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.gentofte university hospital|hellerup||denmark` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01374594.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01374594*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*